IP Library › Granted Patent US 8,058,255
Granted Patent B2
US 8,058,255 · App. 12/484,948 · Granted Nov 15, 2011

Methods and compositions concerning siRNA's as mediators of RNA interference

Assignee: Applied Biosystems, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,058,255
App. No.
12/484,948
Granted
Nov 15, 2011
Kind
B2
Abstract

The present invention concerns an isolated siRNA of from about 5 to about 20 nucleotides that mediates RNA interference. Also disclosed are methods of reducing expression of a target gene in a cell comprising obtaining at least one siRNA of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 basepairs in length; and delivering the siRNA into the cell. The siRNAs can be chemically synthesized RNA or an analog of a naturally occurring RNA.

Claims (21)

1. A composition comprising isolated dsRNA, wherein the isolated dsRNA comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13; SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17; SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30; SEQ ID NO: 31, and SEQ ID NO: 32.

2. The composition of claim 1 , wherein the dsRNA comprises a terminal 3′ hydroxyl group.

3. The composition of claim 1 , wherein the dsRNA is chemically synthesized dsRNA.

4. The composition of claim 1 , wherein the dsRNA is formulated with a pharmaceutically acceptable composition.

5. The composition of claim 1 , wherein the isolated dsRNA comprises SEQ ID NO:11.

6. The composition of claim 1 , wherein the isolated dsRNA comprises SEQ ID NO:12.

7. The composition of claim 1 , wherein the isolated dsRNA comprises SEQ ID NO:13.

8. The composition of claim 1 , wherein the isolated dsRNA comprises SEQ ID NO:14.

9. The composition of claim 1 , wherein the isolated dsRNA comprises SEQ ID NO:15.

10. The composition of claim 1 , wherein the isolated dsRNA comprises SEQ ID NO:16.

11. The composition of claim 1 , wherein the isolated dsRNA comprises SEQ ID NO:17.

12. The composition of claim 1 , wherein the isolated dsRNA comprises SEQ ID NO:18.

13. The composition of claim 1 , wherein the isolated dsRNA comprises SEQ ID NO:19.

14. The composition of claim 1 , wherein the isolated dsRNA comprises SEQ ID NO:20.

15. The composition of claim 1 , wherein the isolated dsRNA comprises SEQ ID NO:21.

16. The composition of claim 1 , wherein the isolated dsRNA comprises SEQ ID NO:22.

17. The composition of claim 1 , wherein the isolated dsRNA comprises SEQ ID NO:31.

18. The composition of claim 1 , wherein the isolated dsRNA comprises SEQ ID NO:32.

19. A method of reducing expression of a target gene in a cell comprising:

a) obtaining at least one siRNA of claim 1 ; and

b) delivering the siRNA into the cell.

Assignments (5)
MERGER Recorded Oct 11, 2011
From: APPLIED BIOSYSTEMS, INC.
To: APPLIED BIOSYSTEMS, LLC
Reel/Frame 027041/0884 →
MERGER Recorded Oct 4, 2011
From: ATOM ACQUISITION CORPORATION
To: APPLIED BIOSYSTEMS INC.
Reel/Frame 027013/0924 →
MERGER Recorded Sep 23, 2011
From: APPLERA CORPORATION
To: APPLIED BIOSYSTEMS INC.
Reel/Frame 026954/0938 →
MERGER Recorded Sep 21, 2011
From: AMBION, INC.
To: APPLERA CORPORATION
Reel/Frame 026942/0052 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2011
From: FORD, LANCE P.; KREBS, JOSEPH
To: AMBION, INC.
Reel/Frame 026921/0733 →
Continuity (2)
Continuation 11020560 · Dec 23, 2004
Related Publication 20100159591A1 · Jun 24, 2010